When it comes to stocks with the potential to make big moves in the first quarter of 2021, the author of today’s article advises that “There are at least three in the biotech space with enormous catalysts on the way that could drive their prices higher or lower overnight.” Those enormous catalysts, of course, are FDA approval decisions. For the three biotech stocks in question, their drug/treatment candidates under review, and when the FDA is expected to issue its decisions for each, CLICK HERE.